With Fundraising, A Track Record Matters: GeoVax's David Dodd

By Ben Comer, Chief Editor, Life Science Leader

David Dodd, chairman and CEO at GeoVax, has seen a lot over 45 years in the biopharmaceuticals industry, from commercial roles at Big Pharmas including Abbott and Bristol-Myers Squibb, to helming scrappy startups and founding a life sciences investment and consulting firm. In this Q&A, Dodd describes the current fundraising environment and challenges he faced in becoming CEO at GeoVax, a clinical-stage oncology and infectious diseases company, and how he’s managed to increase the company’s active clinical program count at a time when many small biotechs are struggling to fund a single lead candidate.